Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
企業コードIMNM
会社名Immunome Inc
上場日Oct 02, 2020
設立日2015
最高経営責任者「CEO」Dr. Clay B. Siegall, Ph.D.
従業員数118
証券種類Ordinary Share
決算期末Oct 02
本社所在地18702 N. Creek Parkway
都市BOTHELL
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号98011
電話番号16103213700
ウェブサイトhttps://immunome.com/
企業コードIMNM
上場日Oct 02, 2020
設立日2015
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし